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in tumour xenografts and patients with small-cell lung
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Summary The neural cell adhesion molecule (NCAM) is highly expressed on the surface of small-cell-lung cancer (SCLC) cells. We have
produced a monoclonal antibody, NY3D11, that binds to NCAM to investigate whether this antigen could be used to develop antibody-directed
therapy for SCLC. 1251-labelled IgG and F(ab')2 fragments of NY3D11 localized selectively in human SCLC xenografts grown in nude mice.
The human biodistribution of 131I-labelled NY3D11 after intravenous administration was investigated by gamma-camera imaging in six patients
with SCLC. Three patients received IgG and three received F(ab')2. No evidence of localization to primary tumours or metastases was seen
and antibody accumulated rapidly in the liver and bone marrow. The probable explanation for this distribution is that NY3D11 reacted with
soluble NCAM or natural killer cells that possess the CD56 (NCAM) antigen.
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The mortality of patients with small-cell lung cancer (SCLC)
remains greater than 90% at 2 years after diagnosis and new thera-
peutic approaches areurgently needed to improve the outcome ofthe
disease (Souhami et al, 1990). The tumour is characterized by its
initial responsiveness to chemotherapy, producing complete remis-
sion in about 50% of patients and early relapse. Eradication of
persistent micrometastases at the end of chemotherapy would
prevent the development of chemoresistant tumour relapse.
Antibody-directed therapy is one strategy used to target therapy
specifically to the tumour site. Monoclonal antibodies recognizing
tumour-associated surface antigens have been shown to localize
specifically in many different tumour types. Therapy is most likely
to be effective in small tumour foci when the total tumour burden is
low as antibody uptake is mostefficient (Pedley et al, 1987; Olabiran
et al, 1994). Adjuvant antibody therapy in patients with colorectal
cancer has produced encouraging results (Reithmuller et al, 1994)
and antibody-directed therapy of micrometastases of SCLC in the
adjuvant setting could also be an effective new treatment.
The neural cell adhesion molecule (NCAM) is strongly
expressed on the surface of SCLC cells (Souhami et al, 1991;
Rygaard et al, 1992). Anti-NCAM monoclonal antibodies localize
to SCLC xenografts in nude mice and produce regression of
tumours when conjugated to a therapeutic dose of radioisotope
(Boerman et al, 1991; Hosono et al, 1994). NCAM is also
expressed by normal tissues including neural tissue, muscle,
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thyroid epithelium, testicular Leydig cells and natural killer (NK)
cells in blood. It exists in membrane-associated forms and a
soluble form that can be detected in the serum of patients with
SCLC (Jaques et al, 1993). Serum NCAM levels are raised in
patients with active disease and in relapse, suggesting that this
antigen could be a useful target for therapy of micrometastases
(Ledermann et al, 1994).
We have produced a murine monoclonal antibody, NY3D11,
against the NCAM molecule on SCLC. The purpose of this study
was to investigate the biodistribution of radiolabelled NY3D11
whole immunoglobulin and its F(ab')2 fragments in nude mice
bearing SCLC xenografts and to perform a localization study in
patients with SCLC.
MATERIALS AND METHODS
Antibodies
The monoclonal antibody NY3D11 was raised after immunization
of RBS/DNJ mice (Robertsonian 8:12 translocation) with SCLC
cell line UCH10. Spleen cells were fused with the Fox NY, NS1
variant myeloma line. For details see Olabiran et al (1994). In
common with most other anti-NCAM monoclonal antibodies,
NY3D11 binds to immunodominant epitopes located in the 'stem
region' C-terminal of the fifth Ig-like domain of the NCAM
molecule (Gerardy-Schahn et al, 1994). The antibody for patient
administration was purified by affinity chromatography on protein
A-Sepharose from tissue culture supernatant (kindly produced by
Celltech) and tested before clinical use according to guidelines in
the Operation Manualfor the Control ofProduction, Preclinical
Toxicity and Phase I Trials of Anti-tumour Antibodies and
Drug-Antibody Conjugates (1986).
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Figure 1 Radiolocalization index of NY3D11 in nude mice bearing UCH10
SCLC xenografts. E1, RI 24 h; LI, RI 48 h; E, RI 7 days
F(ab')2 fragments
F(ab')2 fragments ofNY3D 1 were prepared from whole antibody
by bromelain digestion (Mariani et al, 1991). In brief, freshly acti-
vated and desalted bromelain was added to the antibody in 0.1 M
sodium acetate/3 mM EDTA pH 5.5 at a ratio of 1:50 (brome-
lain-antibody). The mixture was incubated for 1 h at 37°C, cooled
to 4°C and a small amount of 0.1 M sodium hydroxide added to
bring the pH to 6.0. The antibody/bromelain reaction mixture was
immediately applied to a SP Sepharose column that was washed
with a 5-CV (column volume) gradient of 0.2 M sodium chlo-
ride/0.1 M sodium acetate pH 6.0 to separate the F(ab')2 fragments.
F(ab')2 was then passed down a protein A column to remove
residual whole IgG. The purity ofthe F(ab')2 product was assessed
using sodium dodecyl sulphate polyacrylamide gel and high-
performance liquid chromatography before patient administration.
Radiolabelling
For animal studies IgG and F(ab')2 fragments of NY3D11 were
labelled with 1251 by the iodogen method to a specific activity of
approximately 111 MBq mg-' protein. For patient studies, 0.5-
1.0 mg NY3D11 were labelled with 74 MBq of '3'I initially by the
chloramine-T method (two patients) and subsequently by the
iodogen method.
In vitro studies of radiolabelled NY3D11
Immunoreactivityassay
Immunoreactivity ofthe labelled antibody with glutathione-S-trans-
ferase (GST) NCAM fusion protein (kindly provided by Professor
Frank Walsh, UMDS, London, UK) was tested by enzyme
immunosorbent assay. The GST NCAM fusion protein contained a
peptide sequence from full length human NCAM previously shown
to bind anti-NCAM antibodies. A 96-well plate was coated with
100 ,l ofNCAM fusionprotein 5 ,ug ml-' in carbonate bufferfor2 h
at 37°C. The plate was washed three times with phosphate-buffered
saline/Tween. Non-specific binding was blocked by adding 150p1
of 3% bovine serum albumin (BSA)/PBS to each well for 2 h at
370C. The plate was washed again three times with PBS/Tween. An
aliquot (200 jl) PBS was added to the first well of the row and
100 ,l ofPBS to theremaining wells. Antibody (1 jig) was added to
the first well (to give aconcentration of5 jg ml-'). A serial 1:2 dilu-
tion was made across the rows and the plate was incubated at 37°C
for 1 h. After washing three times with PBS/Tween, 100jil ofalka-
line phosphatase-conjugated anti-mouse IgG was added to each
well. The plate was incubated at 37'C for 1 h and washed three
times with PBS/Tween. Finally, 100 jil offresh p-nitrophenyl phos-
phate substrate was added to each well and colour was allowed to
develop for 1 h at 370C. The absorbance ofeach well was read on a
plate reader at410 nm. Experiments wereperformed in duplicate on
the sameplate. The immunoreactivity ofradiolabelled antibody was
compared with that ofunlabelled antibody.
Aggregate analysis bygel filtration on S300 column
The radiolabelled antibody was diluted 1:50 in PBS/azide and
loaded onto a Sepharose 300 column. The activity of aliquots of
each fraction collected was measured on a gamma-counter.
FACS analysis
Staining ofNK cells with NY3D 11 was investigated using double
immunofluorescence on a FACScan (Beckton Dickinson, UK)
and three different markers of NK cells, CD8 (RFT8 Royal Free
Hospital, Department of Immunology), CD16 (Leu 1 ib, kind gift
from Professor J Thompson, Kentucky University, USA.) and
CD57 (HNK1). Blood was obtained from two healthy donors. A
commercial monoclonal antibody for NCAM, NKH1:CD56,
(Coulter, UK) was used as a positive control.
Animal studies
Establishment ofxenografts in nude mice
The human small-cell lung cancer cell line UCH1O orH69 was used
to establish a xenograft model subcutaneously in the flanks ofnude
(nu/nu) mice. The mice were female, 2-3 months old and weighed
between 20 and 25 g. Subsequent passaging oftumours was carried
out by subcutaneous implantation of small tumour pieces (approxi-
mately 1 mm3). The biodistribution study was commenced when
the tumours reached a size of approximately 1.0 cm3. Immediately
before the study, a xenograft tumour was examined for antigen
expression by immunohistochemistry and binding ofNY3D 11 anti-
body and its F(ab')2 fragments was confirmed.
Immunohistochemistry
Immunohistochemical reactivity of NY3D 11 with bone marrow
and xenograft tissue was assessed using an avidin-biotin peroxi-
dase technique. Xenograft tissue was snap frozen in isopentane,
cooled in liquid nitrogen and 6 jm cryostat sections were cut.
Bone marrow smears and cryostat sections were fixed before
immunohistochemistry with acetone for 10 min.
Biodistribution study
Experiments to confirm specific localization of antibody in SCLC
xenografts were performed with radiolabelled NY3D1 1 and the
control antibody 4120, an IgG, anti-human CD4 (a gift from
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Professor Beverely, ICRF, London, UK). Two groups of 12 mice
bearing UCHl0 xenografts received 10 gg of radiolabelled
NY3D 11 or 4120 by injection into the tail vein. Animals were
given food and water ad libitum. The water contained 0.1% potas-
sium iodide to prevent thyroid uptake of iodide. Groups of four
mice were bled and killed at 24, 48 and 72 h. Tissues were
removed and placed into preweighed tubes filled with 7 M potas-
sium hydroxide. When the tissues had dissolved, samples were
counted on a gamma counter (Pharmacia, 1470 Wizard). The mean
percentage uptake of the injected dose per gram of tissue
(%ID g-') was determined and the tumour-non-tumour ratio was
expressed as the radioimmunolocalization index (RI), calculated
for each tissue according to the formula:
%ID g-' ofNY3D11 in tissue/ %ID g- ofNY3D11 in blood
%ID g-' of4120 in tissue / %ID g-' of4120 in blood
In experiments to compare the biodistribution of radiolabelled
NY3Dl1 IgG and F(ab')2, two groups of eight mice bearing H69
xenografts received IgG (5.3 ,ig) or F(ab')2 (7.1 jg). At 24 h and
72 h, four mice from each group were bled and the following
tissues removed for gamma radiation counting: liver, tumour,
spleen, rectum, kidney, lung and muscle. Femur was taken from
two mice in each group at both time points. Tissues were
processed and analysed as described above.
Patient studies
Patient eligibility
Patients with SCLC, newly diagnosed or undergoing treatment,
age 16-80 years, and WHO performance status 0-3 were eligible
for the study. Patients with a history of allergy to iodine or
immunoglobulins or a positive skin test to intradermal administra-
tion of antibody were excluded. Written informed consent was
obtained from participants and the study was approved by the
ethics committees ofparticipating centres.
Preliminary investigations
Chest radiography, bone scanning and ultrasonography of the
liver were used to assess tumour site(s). Full blood count, urea,
electrolytes, creatinine, liver function tests and thyroid function
tests were performed before antibody injection.
Administration ofantibody
To prevent accumulation of radioactivity in the thyroid gland,
patients received potassium iodate 85 mg t.d.s. for 7 days
commencing 24 h before administration of radiolabelled antibody.
Before the intravenous injection, patients received an intradermal
injection in the forearm of0.1 ml (1-2 jig) ofradiolabelled antibody.
At an adjacent site 0.1 ml of0.9% saline was injected intradermally
and the skin reaction at both injection sites was compared after
15 min. If erythema at the test site was greater than at the control
site, intravenous administration of antibody did not proceed. The
antibody (0.5-1 mg) was injected intravenously over 5 min.
Study parameters
Gamma camera imaging
Patients were scanned at 24, 48 and 72 h after injection ofantibody.
Scanning was performed using a large field ofview gamma-camera
with ahigh-energy parallel-hole collimator and an on-line computer.
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Figure 2 Biodistribution of whole ['25l]NY3D11 and F(ab')2 in nude mice
bearing H69 SCLC xenografts (expressed as percentage of injected dose
per gram of tissue). Error bars show standard deviation. *, 24 h; E1, 72 h
Venous bloodsampling
To determine the elimination ofantibody from the circulation, 5 ml
ofvenous blood were withdrawn immediately after injection (from
the contralateral arm) and at 24, 48 and 72 h. Blood was stored in
British Journal ofCancer (1998) 77(1), 103-109 C CancerResearch Campaign 1998106 D Omadel etal
preweighed EDTA bottles and activity was measured after several
weeks when sufficient decay allowed accurate counting.
RESULTS
Biodistribution studies in mice
Tumourlocalization ofNY3D11
Specific uptake of ['251]NY3DII was seen in nude mice bearing
UCH10 xenograft tumours compared with the uptake of the non-
specific antibody 4120. Maximum tumour localization occurred at
48 h after intravenous injection. The mean uptake of radioactivity
in tumour atthis time was 15.9% ID g-' (s.d. 2.46) forNY3D11 and
5.65% ID g-1 (s.d. 1.17) for 4120. Prolonged retention of radio-
activity in the tumour was seen; 13.7% ID g' (s.d. 3.42) of
NY3Dl1, five times the amount ofnon-specific antibody remained
at 7 days. The radiolocalization index (Figure 1), which measures
specific accumulation of NY3Dl1 in the tumour, increased from
1.8 at 24 h after injection to 3.7 at 7 days. For normal tissues this
value ranged from 0.7 to 1.0 at 24 h and from 0.4 to 1.0 at 7 days.
NY3D11 IgG
3 -
2.5 -
0
1.5 -
1-
0.5 -
0 -
Biodistribution of whole IgG vs F(ab')2
The biodistribution ofradiolabelled NY3D11 IgG andF(ab')2 at 24
and 72 h are shown in Figures 2 and 3. At 24 h, the % ID g-1
tumour ofIgG vs F(ab')2 was 19.7% vs 7.1% and at 72 h 26.7% vs
3.81% respectively. There was no evidence oflocalization to bone
marrow or liver. These results show that amuch greaterproportion
of injected IgG was taken up and retained by the tumour
xenografts compared with the F(ab')2 fragments. However, despite
the smaller absolute uptake of F(ab')2 fragments into tumour, the
tumour-blood ratios ofIgG vs F(ab')2 at 24 and 72 h were 1.42 vs
6.18 and 2.54 vs 23.1.
Patient studies
The patient characteristics are summarized in Table 1. There were
no positive skin reactions and no immediate or delayed adverse
effects after injection of the antibody. No haematological or
biochemical toxicity was observed. The first three subjects were
studied with NY3D1 1 IgG after mouse studies indicated that
uptake ofIgG in tumourxenografts was higherthan forF(ab')2. No
antibody localization was detected in primary tumours or metas-
tases but accumulation in the bone marrow (spine and pelvis) and
liver was observed in all subjects. The spleen was visualized in
one patient (subject 3). The mouse studies had shown that F(ab')2
might be more favourable for imaging (high tumour:blood ratio)
and three further subjects were studied with NY3D1 1 F(ab')2. The
results were similar to those of IgG. No primary tumours or
metastases were imaged but antibody again accumulated in bone
marrow and liver. First-phase clearance of radiolabelled antibody
from blood was rapid with less than 25% of initial activity
remaining at 24 h (Figure 4). Whole antibody and F(ab')2 were
cleared at similar rates except in one patient (subject 4).
In vitro antibody studies
Aggregation
Antibody showed no evidence ofaggregation in vitro either before
or after radiolabelling. Incubation ofradiolabelled antibody with a
patient serum orpreviously stored serum with high soluble NCAM
did not produce aggregation.
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Figure 3 Biodistribution of whole [125l]NY3D11 and F(ab')2 in nude mice
bearing H69 SCLC xenografts (expressed as tissue to blood ratios). *, 24 h;
E1, 72 h
Immunoreactivity
After labelling using the chloramine-T method (subjects 1 and 2),
comparison of the immunoreactivity of cold NY3D11 with
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Table 1 Patient characteristics and antibody received
Subject Age (years) Primary Metastases Antibody Dose (mg)
1 64 Right hilum - Whole Ig 0.5
2 80 Right lung (diffuse) Bone Whole Ig 0.5
3 68 Left hilum - Whole Ig 0.5
4 68 Mass left lung - F(ab')2 0.5
5 47 Left hilar mass Liver F(ab')2 1
6 59 Left hilar mass Supraclavicular F(ab')2 1
mass
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Figure 4 Clearance of radiolabelled antibody from blood after injection at
0 hrs. O, patient 1; O, patient 2; 0, patient 3; A, patient 4; i, patient 5;.,
patient 6
radiolabelled NY3D 11 demonstrated approximately 50% loss of
immunoreactivity. When the iodogen method was used for
subjects 3-6, there was only a small reduction of immuno-
reactivity after radiolabelling.
Immunohistochemistry ofSCLCxenografts andnormal
bone marrow
Immunohistochemistry ofSCLC xenografts removed immediately
before biodistribution studies confirmed that NY3D 11 whole IgG
and its F(ab')2 fragments reacted with the tumour. After studies in
humans demonstrated localization in bone marrow, immunohisto-
chemistry on ten normal bone marrow samples was performed to
investigate whether this distribution could be explained by reac-
tion with a cellular element in bone marrow. These studies showed
no evidence ofantibody binding to normal bone marrow cells.
FACS analysis
The H69 SCLC cell line bound at least six to seven times as much
NKH1 as NY3D 11, despite the use of NY3D 11 over a concentra-
tion range of 1-100 ,ug ml'. Similarly, the percentage of CD8,
CD16 orCD57 positive cells (NK cells) that stained with NY3D 1I
or NKH1 was always much less for NY3D 11 than NKH1 (approx-
imately 40% and 90% respectively) and the mean fluorescence
intensity (MFI) ofNKH1 on NKcells was six- to sevenfold greater
than that ofNY3Dl 1. However, the MFI values suggested that NK
cells could still bind large amounts ofNY3Dl 1.
DISCUSSION
These studies demonstrate that NY3D 11 localized well to SCLC
xenografts in mice but not to SCLC tumours in patients in whom it
was cleared rapidly from blood and accumulated in bone marrow
and liver. A previous study in patients with SCLC using the
NCAM monoclonal MAb 123C also found no localization to
primary tumours, although a single liver metastasis was detected
(Michalides et al, 1994). This negative result occurred despite
immunoscintigraphy studies in mice that suggest that MAb 123C3
has superior localization compared with other cluster-1 antibodies
because of its internalization (Kwa et al, 1996). However, it is
clear that other anti-NCAM antibodies that do not internalize can
also localize well in mouse studies (Boerman et al, 1991; Waibel et
al, 1993; Hosono et al, 1994) and the present study further high-
lights that successful localization of antibodies in mice is not
necessarily reproduced in human studies. The reasons for this
disparity between mice and man need to be understood for the
successful future development of anti-NCAM antibodies.
The reticuloendothelial system (RES) canrecognize and remove
foreign particles from the circulation. Some antibody binding and
uptake may occur through non-specific Fc receptor interactions.
Blood clearance is also a function of size of the antibody. Murine
F(ab')2 fragments are cleared more rapidly from blood than intact
IgG in mice but clearance in man is similar (Lane et al, 1994). We
observed a similar blood distribution ofintact antibody and F(ab')2
fragments in patients implying that Fc interactions were not an
important factor affecting blood clearance. Aggregation of anti-
body could also explain the observed distribution but there was no
evidence from gel chromatography that aggregation had occurred
during storage or afterradiolabelling. The possibility that antibody
combined with soluble NCAM in serum to form aggregates was
also considered but no aggregation was seen after incubation with
patient serum or serum containing high levels of soluble NCAM.
Although Sepharose chromatography did not suggest binding to
soluble NCAM, low-affinity antibody may occasionally not
survive column chromatography. NY3D11 appears to have a rela-
tively low affinity for NCAM and therefore aggregation cannot be
completely excluded.
Gamma-camera scanning demonstrated accumulation in spine,
pelvis and ribs that suggested that antibody was localizing in the
bone marrow. However, no binding of antibody was seen in any
of the normal bone marrow aspirates examined by immuno-
histochemistry. It is known that natural killer (NK) cells express
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NCAM (CD56) (Hida et al, 1991). When an epitope is present at
low levels or affinity for the epitope is weak, immunohistochem-
istry may not be sufficiently sensitive to detect binding. NK cells
comprise a very small percentage of bone marrow cells and this
may explain why they were not detected by immunohistochem-
istry. FACS analysis subsequently showed that NY3D 1 was six to
seven times less immunoreactive than NKH1 on control H69 cells
and NK cells. NY3D11 and NKHl recognize similar epitopes on
NCAM (Gerardy-Schahn et al, 1994). Despite this relatively
low immunoreactivity, the mean fluorescence intensity values
recorded in the FACS studies suggested that NK cells might still
bind large amounts of NY3D11. Injected antibody may therefore
have bound to circulating NK cells but excess localization to
spleen would be expected and this was observed in only one
patient in this study.
The importance of immunoreactivity of an antibody with its
epitope for tumour localization remains uncertain. Some authors
suggest that antibody uptake and penetration into tumours is
enhanced by high affinity radioimmunoconjugates (Schlom et al,
1992), whereas others propose that interaction of high-affinity
antibodies at the surface of a tumour prevents penetration
(Fujimori et al, 1989). Radioactive labelling of NY3D1 1 by the
chloramine-T method led to a 50% loss of immunoreactivity
compared with unlabelled antibody. After the labelling technique
was changed to the iodogen method, the reduction in immuno-
reactivity was small. However, improvement in immunoreactivity
failed to enhance tumour localization ofantibody.
The accessibility ofepitopes on tumour cells is also likely to be
important for successful antibody localization (Pervez et al, 1988).
The limited success ofradioimmunotherapy and wide variations in
antibody localization amongst patients with cancers of the same
histology has been attributed in part to heterogeneity of antigen
distribution (Edwards, 1985). The distribution of NCAM expres-
sion in SCLC tumours in vivo has not been studied as it is difficult
to obtain tumour samples, but accessibility of NCAM epitope to
circulating antibodies in patients may be restricted. Antigens in
vivo may be expressed at preferential sites (Pervez et al, 1989) and
the basal lamina may represent a physical barrier to extravasated
antibodies (Dvorak et al, 1991). In colorectal adenocarcinomas,
CEA epitopes expressed on the lumenal surface ofmalignant acini
or in the cytoplasm may be inaccessible to antibodies in vivo,
whereas epitopes on the basal or basolateral aspects of glandular
structures are more readily accessible (Boxer et al, 1994).
However, it has been shown that CEA epitopes on lung cancer are
accessible to circulating antibodies. When CEA was targeted in 21
patients with active SCLC, tumour was successfully imaged in 13
patients (62%) and 18 out of 38 known disease sites were imaged
(Macmillan et al, 1993). This antigen is a promising target for
further studies. The epithelial glycoprotein EGP-2 on SCLC has
also been successfully targeted in patients (Kosterink et al, 1995).
Six patients with SCLC were studied with indium-labelled mono-
clonal antibody MOC-31, which was identified as a cluster 2 anti-
body at the First International Workshop on SCLC antigens.
Scintigraphy detected primary tumour or metastases in five
patients and further studies are indicated.
In summary, reaction with soluble NCAM or circulating NK
cells was the most likely reason for the failure of NY3Dll to
localize to tumour in these studies. NCAM does not now appear to
be a suitable target for antibody directed therapy in SCLC but the
lung cancer antigen workshops have identified other surface anti-
gens which should be investigated.
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